ReviewJournal of clinical medicine2026
Is There a Way to Break the Glass Ceiling in the Diagnosis and Treatment of Extraintestinal Manifestations (EIMs) in the Course of Inflammatory Bowel Diseases? A Comprehensive Review of Diagnosis, Pathophysiology, and Treatment of EIM.
Review in Journal of clinical medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory bowel diseases (IBDs), particularly Crohn's disease (CD) and ulcerative colitis (UC), are chronic disorders that affect not only the gastrointestinal tract but also other organ systems through extraintestinal manifestations (EIMs). It is estimated that EIM may occur in up to half of all patients, with at least two different EIM present in 20% of cases and preceding the diagnosis of IBD by approximately five months in 26% of cases. The most frequently reported manifestations include dermal lesions, spondyloarthropathy, and hepatobiliary disorders, although ocular involvement is also observed, significantly impairing patients' daily functioning. Given the profound impact on quality of life (QoL) and the associated diagnostic challenges, this article provides an overview of the epidemiology, pathophysiological mechanisms, and current diagnostic and therapeutic strategies for EIM. Special emphasis is placed on the importance of early recognition and coordinated, multidisciplinary care involving gastroenterology, rheumatology, dermatology, ophthalmology, and other specialties. The roles of genetic, immunological, and environmental factors in the development of these complications are also discussed, along with recent therapeutic advances, including biologics and small molecules. Future directions highlight the need for multicenter studies aimed at improving both prophylactic and therapeutic strategies. This comprehensive narrative review aims to summarize current evidence on the epidemiology, pathophysiology, diagnosis, and treatment of extraintestinal manifestations in IBD, with particular emphasis on their early recognition, multidisciplinary management, and clinical implications. We also discuss emerging therapeutic strategies, screening and referral approaches, and areas requiring further research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.